Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, Germany’s Merck and Japan’s Ono Pharmaceutical for an experimental cancer treatment that could be valued at more than $8…